OBJECTIVE: To describe the effect of a combination prophylactic regimen of levofloxacin, a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class, with either penicillin or doxycycline on the changing epidemiology of bacterial infections and antimicrobial resistance patterns of isolated organisms in the allogeneic hematopoietic stem cell transplant (HSCT) patient population. PATIENTS AND METHODS: We conducted a single-center, retrospective cohort study of all allogeneic HSCT recipients from January 1, 2003, through August 31, 2008, who received prophylactic levofloxacin in combination with penicillin (or with doxycycline in penicillin-allergic patients) from allogeneic stem cell infusion until neutrophil engraftment. RESULTS: Of the 258 patients who underwent allogeneic HSCT during the study period, 231 received levofloxacin prophylaxis, 76 (33%) of whom developed an infection within 3 months after transplant. Over time, the ratio of gram-positive to gram-negative (GN) infections decreased from 2.11 in 2004, the first year that GN organisms were isolated, to 1.11 in 2008 (P=.20). Emergence of fluoroquinolone-resistant GN bacteria was observed (P=.02), whereas resistance to extended-spectrum beta-lactams did not change over time. Combined vancomycin-resistant enterococci colonization and infection rates increased during the study period (P=.04). Clostridium difficile colitis was uncommon. CONCLUSION: Levofloxacin with penicillin or doxycycline prophylaxis may contribute to the emergence of resistant GN infections in allogeneic HSCT recipients over time. Our findings provide additional support for the current standard of practice of administering empiric monotherapy with an antipseudomonal beta-lactam if these patients develop fever or are suspected to have an infection.
OBJECTIVE: To describe the effect of a combination prophylactic regimen of levofloxacin, a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class, with either penicillin or doxycycline on the changing epidemiology of bacterial infections and antimicrobial resistance patterns of isolated organisms in the allogeneic hematopoietic stem cell transplant (HSCT) patient population. PATIENTS AND METHODS: We conducted a single-center, retrospective cohort study of all allogeneic HSCT recipients from January 1, 2003, through August 31, 2008, who received prophylactic levofloxacin in combination with penicillin (or with doxycycline in penicillin-allergic patients) from allogeneic stem cell infusion until neutrophil engraftment. RESULTS: Of the 258 patients who underwent allogeneic HSCT during the study period, 231 received levofloxacin prophylaxis, 76 (33%) of whom developed an infection within 3 months after transplant. Over time, the ratio of gram-positive to gram-negative (GN) infections decreased from 2.11 in 2004, the first year that GN organisms were isolated, to 1.11 in 2008 (P=.20). Emergence of fluoroquinolone-resistant GN bacteria was observed (P=.02), whereas resistance to extended-spectrum beta-lactams did not change over time. Combined vancomycin-resistant enterococci colonization and infection rates increased during the study period (P=.04). Clostridium difficilecolitis was uncommon. CONCLUSION:Levofloxacin with penicillin or doxycycline prophylaxis may contribute to the emergence of resistant GN infections in allogeneic HSCT recipients over time. Our findings provide additional support for the current standard of practice of administering empiric monotherapy with an antipseudomonal beta-lactam if these patients develop fever or are suspected to have an infection.
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: Brahm H Segal; Alison G Freifeld; Lindsey Robert Baden; Arthur E Brown; Corey Casper; Erik Dubberke; Michael Gelfand; John N Greene; Michael G Ison; James I Ito; Judith E Karp; Daniel R Kaul; Earl King; Emily Mackler; Guido Marcucci; Jose G Montoya; Ashley Morris Engemann; Ken Rolston; Angelina S The Journal: J Natl Compr Canc Netw Date: 2008-02 Impact factor: 11.908
Authors: Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh Journal: Biol Blood Marrow Transplant Date: 2009-10 Impact factor: 5.742
Authors: Malgorzata Mikulska; Valerio Del Bono; Anna Maria Raiola; Barbara Bruno; Francesca Gualandi; Domenico Occhini; Carmen di Grazia; Francesco Frassoni; Andrea Bacigalupo; Claudio Viscoli Journal: Biol Blood Marrow Transplant Date: 2009-01 Impact factor: 5.742
Authors: H Imran; I M Tleyjeh; C A S Arndt; L M Baddour; P J Erwin; C Tsigrelis; N Kabbara; V M Montori Journal: Eur J Clin Microbiol Infect Dis Date: 2007-10-16 Impact factor: 3.267
Authors: Sarah Alexander; Michael Nieder; Danielle M Zerr; Brian T Fisher; Christopher C Dvorak; Lillian Sung Journal: Pediatr Blood Cancer Date: 2011-11-18 Impact factor: 3.167
Authors: Arianna Miles-Jay; Susan Butler-Wu; Ali Rowhani-Rahbar; Steven A Pergam Journal: Biol Blood Marrow Transplant Date: 2014-12-11 Impact factor: 5.742
Authors: Susan K Seo; Kun Xiao; Yao-Ting Huang; Ubonvan Jongwutiwes; Dick Chung; Molly Maloy; Sergio Giralt; Juliet N Barker; Ann A Jakubowski; Genovefa A Papanicolaou Journal: J Infect Date: 2014-06-12 Impact factor: 6.072